For several types of cancer, persistently high levels of the soluble factor TGF-beta in the blood after surgery, chemotherapy, or radiation therapy correlate with increased risk of early metastasis and a poor prognosis.
The most common cause of infant hospitalization in the United States, respiratory syncytial virus, infects virtually all children by age two. Along with the influenza virus, RSV is a major contributor to the approximately two million infant deaths worldwide caused every year by respiratory infections, according to the World Health Organization.
A mind-altering mutation in mice results in an enhanced long-term memory, researchers report in the April 6, 2007, issue of the journal Cell, published by Cell Press. These findings point to a potential target for the development of a drug to treat memory loss, according to the researchers.
Have you ever walked by someone listening to their i-Pod loud enough for you recognize the song? Studies have shown noise-induced hearing loss is going to become the next big epidemic affecting our younger generation though the effects won?t show until it is too late to treat.
Living Cell Technologies Limited announced it has published evidence outlining the survival and identification of live porcine islet cells and insulin production in a human patient 10 years after receiving a pig islet cell transplant.
New research by Iowa State University psychologists provides more concrete evidence of the adverse effects of violent video game exposure on the behavior of children and adolescents.
Brain damage that was thought to be caused by hypoglycemic coma actually occurs when glucose is administered to treat the coma, according to a study in rodents led by researchers at the San Francisco VA Medical Center.
The common painkiller, ibuprofen, may boost the likelihood of heart problems in high risk patients who have osteoarthritis, suggests research published ahead of print in the Annals of the Rheumatic Diseases.
Will you lose weight and keep it off if you diet? No, probably not, UCLA researchers report in the April issue of American Psychologist, the journal of the American Psychological Association.
First large, randomized Phase III study of ERBITUX with chemotherapy in recurrent and/or metastatic head and neck cancer meets primary endpoint of improving overall survival.